BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 23688409)

  • 1. Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis.
    Park YS; Lee CH; Kim BH; Lee J; Choi JW; Kim KA; Ahn JH; Park CM
    Magn Reson Imaging; 2013 Sep; 31(7):1137-42. PubMed ID: 23688409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
    Kim HY; Choi JY; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
    Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
    Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T.
    Lim S; Kim YK; Park HJ; Lee WJ; Choi D; Park MJ
    J Magn Reson Imaging; 2014 May; 39(5):1238-45. PubMed ID: 24136725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.
    Frericks BB; Loddenkemper C; Huppertz A; Valdeig S; Stroux A; Seja M; Wolf KJ; Albrecht T
    AJR Am J Roentgenol; 2009 Oct; 193(4):1053-60. PubMed ID: 19770329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.
    Golfieri R; Garzillo G; Ascanio S; Renzulli M
    Dig Dis; 2014; 32(6):696-704. PubMed ID: 25376286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detectability of hepatocellular carcinoma by gadoxetate disodium-enhanced hepatic MRI: tumor-by-tumor analysis in explant livers.
    Nakamura Y; Tashiro H; Nambu J; Ohdan H; Kakizawa H; Date S; Awai K
    J Magn Reson Imaging; 2013 Mar; 37(3):684-91. PubMed ID: 23055436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
    Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
    J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
    Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
    Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
    Kim JE; Kim SH; Lee SJ; Rhim H
    AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging.
    Korkusuz H; Knau LL; Kromen W; Bihrer V; Keese D; Piiper A; Vogl TJ
    J Magn Reson Imaging; 2012 Jun; 35(6):1397-402. PubMed ID: 22267126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of focal liver lesions with gadoxetic acid-enhanced MRI: is a shortened delay time possible by adding diffusion-weighted imaging?
    Kim MY; Kim YK; Park HJ; Park MJ; Lee WJ; Choi D
    J Magn Reson Imaging; 2014 Jan; 39(1):31-41. PubMed ID: 24115329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
    Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
    J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?
    Bashir MR; Gupta RT; Davenport MS; Allen BC; Jaffe TA; Ho LM; Boll DT; Merkle EM
    J Magn Reson Imaging; 2013 Feb; 37(2):398-406. PubMed ID: 23011874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.